<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02547675</url>
  </required_header>
  <id_info>
    <org_study_id>CO-1686-031</org_study_id>
    <nct_id>NCT02547675</nct_id>
  </id_info>
  <brief_title>Rociletinib (CO-1686) USA Expanded Access Program</brief_title>
  <official_title>An Expanded Access Protocol of Oral Rociletinib (CO-1686) as Epidermal Growth Factor Receptor (EGFR)-Directed Therapy for Patients With EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC) With the T790M Resistance Mutation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Clovis Oncology, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Clovis Oncology, Inc.</source>
  <brief_summary>
    <textblock>
      To provide access to rociletinib for patients with advanced or metastatic EGFR-mutant NSCLC&#xD;
      who have been treated previously with EGFR directed therapy and have evidence of a T790M&#xD;
      mutation (T790M+).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open-label, multi-center study in the US, which allows for expanded access to&#xD;
      rociletinib for patients with advanced or metastatic, EGFR-mutant T790M+ NSCLC who were&#xD;
      previously treated with at least one prior EGFR TKI therapy (â‰¥2nd line). Patients will&#xD;
      receive oral rociletinib twice daily on study as long as they have clinical benefit and until&#xD;
      they have access to FDA-approved rociletinib.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>No longer available</overall_status>
  <study_type>Expanded Access</study_type>
  <condition>Non-small Cell Lung Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rociletinib</intervention_name>
    <description>Rociletinib will be administered to patients orally</description>
    <other_name>CO-1686</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  Unresectable locally advanced or metastatic NSCLC with EGFR activating mutation&#xD;
             (excluding exon 20 insertion) and presence of the T790M mutation&#xD;
&#xD;
          -  Prior treatment with an approved or experimental EGFR-directed therapy&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status 0-1&#xD;
&#xD;
          -  Adequate hematological and biological function&#xD;
&#xD;
          -  Written informed consent on an Institutional Review Board (IRB)/Independent Ethics&#xD;
             Committee (IEC)-approved ICF before any study-specific evaluation&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  Eligibility for other enrolling clinical trials of rociletinib&#xD;
&#xD;
          -  Leptomeningeal carcinomatosis or other untreated or symptomatic CNS metastases&#xD;
             (asymptomatic CNS metastases allowed if clinically stable without requirement for&#xD;
             steroid dose increase for at least 4 weeks)&#xD;
&#xD;
          -  History of prior interstitial lung disease&#xD;
&#xD;
          -  Concurrent use of QT-prolonging medication&#xD;
&#xD;
          -  Cardiac abnormalities:&#xD;
&#xD;
               -  Clinically significant abnormal 12-lead ECG, QT interval corrected using&#xD;
                  Fridericia's method (QTcF) &gt; 450 ms&#xD;
&#xD;
               -  Inability to measure QT interval on ECG&#xD;
&#xD;
               -  Personal or family history of long QT syndrome&#xD;
&#xD;
               -  Implantable pacemaker or implantable cardioverter defibrillator&#xD;
&#xD;
               -  Resting bradycardia &lt; 55 beats/min&#xD;
&#xD;
          -  Presence of serious or unstable concomitant systemic disorder incompatible with the&#xD;
             clinical study (eg, substance abuse, uncontrolled intercurrent illness including&#xD;
             active infection, arterial thrombosis, symptomatic pulmonary embolism, and other&#xD;
             active malignancy associated with life expectancy of less than 1 year)&#xD;
&#xD;
          -  Pregnant or breastfeeding females and male or female patients who refuse to use&#xD;
             adequate contraception during the study and for 12 weeks after the last dose of&#xD;
             rociletinib&#xD;
&#xD;
          -  Any contraindication, allergy, or hypersensitivity to rociletinib or excipients&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <location>
    <facility>
      <name>Mayo Clinic Arizona</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Compassionate Care Research Group, Inc.</name>
      <address>
        <city>Fountain Valley</city>
        <state>California</state>
        <zip>92866</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pacific Cancer Care</name>
      <address>
        <city>Monterey</city>
        <state>California</state>
        <zip>93940</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sutter Cancer Institute</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95816</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCSF Helen Diller Family Comprehensive Cancer Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Halifax Health - Center for Oncology</name>
      <address>
        <city>Daytona Beach</city>
        <state>Florida</state>
        <zip>32114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UF Health Center Orlando</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henry Ford Hospital</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Billings Clinic</name>
      <address>
        <city>Billings</city>
        <state>Montana</state>
        <zip>59101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tulsa Cancer Institute</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74146</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2018</verification_date>
  <study_first_submitted>September 10, 2015</study_first_submitted>
  <study_first_submitted_qc>September 10, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 11, 2015</study_first_posted>
  <last_update_submitted>September 24, 2018</last_update_submitted>
  <last_update_submitted_qc>September 24, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">September 25, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

